RxDoctor Payments Data

Dawn Burke

Adult Health · Fishers, INNPI 1093049819

Payments from drug & device makers

$818in general payments, 2019–2025

Across 34 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$223
  • AbbVie$175
  • GSK$125
  • Paratek Pharmaceuticals, Inc.$99
  • Biohaven Pharmaceutical Holding Company Ltd.$72
  • Hologic Sales And Service, LLC$31
  • plus $94 from 6 others

What the payments were for

  • Food & beverage$818100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$818 in reported general payments places this provider in the 60th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$52,280
Medicare patients
230
Services billed
611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$132,597
MounjaroTirzepatide41$60,962
TrulicityDulaglutide36$44,645
JardianceEmpagliflozin31$37,628
EliquisApixaban29$32,524
JanuviaSitagliptin Phosphate21$24,497
MyrbetriqMirabegron27$13,172
FarxigaDapagliflozin Propanediol13$11,973
LinzessLinaclotide16$11,597
XareltoRivaroxaban16$10,831
SymbicortBudesonide/Formoterol Fumarate31$7,650
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$5,972
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,628
Humalog Kwikpen U-100Insulin Lispro18$4,436
VascepaIcosapent Ethyl12$4,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$223$132,59798 claims
AbbVieLinzess, Synthroid$175$14,98857 claims
GSKAnoro Ellipta$125$5,62812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 391 adult health providers in Indiana.

Other adult health in Fishers

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →